Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | ECE1 | P42892 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1177115 | 0.80 | TDP1 (0.44) | TDP1SLC1A3SLC1A2SLC1A1SMN1; SMN2 | |
| SCHEMBL1176824 | 0.80 | TDP1 (0.44) | TDP1SLC1A3SLC1A2SLC1A1SMN1; SMN2 | |
| SCHEMBL1176819 | 0.80 | TDP1 (0.44) | TDP1SLC1A3SLC1A2SLC1A1SMN1; SMN2 | |
| SCHEMBL8472485 | 0.77 | TDP1 (0.52) | TDP1SLC1A3SLC1A2SLC1A1SMN1; SMN2 | |
| SCHEMBL554957 | 0.76 | TDP1 (0.68) | TDP1SLC1A3SLC1A2SLC1A1SMN1; SMN2 | |
| SCHEMBL5514949 | 0.76 | TDP1 (0.68) | TDP1SLC1A3SLC1A2SLC1A1SMN1; SMN2 | |
| SCHEMBL14803500 | 0.76 | TDP1 (0.68) | TDP1SLC1A3SLC1A2SLC1A1SMN1; SMN2 | |
| SCHEMBL13595128 | 0.74 | TDP1 (0.50) | TDP1SMN1; SMN2 | |
| SCHEMBL9794637 | 0.74 | TDP1 (0.50) | TDP1SMN1; SMN2 | |
| SCHEMBL11417337 | 0.70 | TDP1 (0.54) | TDP1SLC1A1SMN1; SMN2MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102245574-A | Compounds, pharmaceutical compositions and methods for treating metabolic disorders | EUROSCREEN SA | 2011-11-16 | — | — | CN | disclosed |